Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.

Biochimica et biophysica acta. General subjects - 1 Jan 2021

Tangella Lokeswari P, Clark Michael E, Gray Elin S

Abstract excerpt

BACKGROUND: The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have improved survival rates in a significant proportion of patients. Nonetheless, the emergence of resistance to treatment remains inevitable in most patients. SCOPE OF REVIEW: Here, we review known and emerging molecular mechanisms that underlay the development of resistance to MAPK inhibition in melanoma cells and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 32956754
DOI: 10.1016/j.bbagen.2020.129736

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.PMID 32956754Read ↗

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSemantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.Semantic proximity Read ↗

BRAF inhibitors: resistance and the promise of combination treatments for melanomaSemantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Resistance to BRAF-targeted therapy in melanoma.Semantic proximity Read ↗

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.Semantic proximity Read ↗

Targeted therapy resistance mechanisms and therapeutic implications in melanoma.Semantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.